Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Gains from Investment Securities (2017 - 2025)

Catheter Precision (VTAK) has disclosed Gains from Investment Securities for 9 consecutive years, with $24000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 44.13% to $24000.0 in Q3 2025 year-over-year; TTM through Mar 2025 was $500000.0, a 18.65% decrease, with the full-year FY2024 number at $1315.0, down 93.87% from a year prior.
  • Gains from Investment Securities was $24000.0 for Q3 2025 at Catheter Precision, down from $500000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $214.7 million in Q3 2023 to a low of $741.0 in Q3 2022.
  • A 5-year average of $12.7 million and a median of $21465.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 28967781.24% in 2023, then tumbled 99.99% in 2024.
  • Catheter Precision's Gains from Investment Securities stood at $2094.0 in 2021, then tumbled by 52.72% to $990.0 in 2022, then soared by 2068.18% to $21465.0 in 2023, then surged by 323.95% to $91000.0 in 2024, then tumbled by 73.63% to $24000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Gains from Investment Securities are $24000.0 (Q3 2025), $500000.0 (Q1 2025), and $91000.0 (Q4 2024).